January 2008 Br J Cardiol 2008;15:7-11
BJCardio editorial team
Table 1. Results at 10 months In the current study, the GenousTM stent was associated with significantly fewer major adverse cardiac events (MACE) than the TaxusTMor CypherTM drug-eluting stents. The study, presented at the recent Italian Society of Invasive Cardiology by Dr Federico Piscione (Federico II University of Naples, Italy) involved 195 high-risk patients who received either a GenousTM, TaxusTM or CypherTM stent. Dual antiplatelet therapy was given for one month to the patients receiving a GenousTM stent and for nine months to those given one of the drug-eluting stents. “GenousTM is a viable alternative to drug-eluting stents, whi
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits